Accelerate Biomarker-Driven Drug Development with Integrated Tissue and Liquid Biopsy Analyses

Despite huge progress in precision oncology, access to comprehensive biomarker testing still limits widespread adoption and development of precision treatments. In this webinar, Dr. Mark Sausen reviews several studies that showcase the value of adding plasma-based genotyping to tissue next-generation sequencing to increase targetable mutation detection and improve delivery of targeted therapies.1,2

See how our comprehensive solid tumor profiling platform for both tissue and plasma samples — offered through both central lab services and kitted solutions — can help bring cutting-edge cancer therapies within reach for all.

Speaker: Mark Sausen, PhD, Vice President,
Technology Innovation at PGDx

Sign up to watch webinar
By filling in this form, you affirm that you have read and understand the Privacy Policy and Terms of Use